A群脑膜炎球菌多糖结合疫苗安全性和免疫原性观察

目的观察评价A群脑膜炎球菌多糖结合疫苗安全性和免疫原性。方法在江苏省射阳县将236名3~4月龄健康婴儿随机分为2组,分别接种试验疫苗和对照疫苗,观察接种后的安全性及2针免疫后1个月、3针免疫后1个月的免疫原性。结果A群脑膜炎球菌多糖结合疫苗无严重的全身反应。试验疫苗组2针免疫后1个月和3针免疫后1个月,抗体几何平均滴度(GMT)与免疫前相比均达到≥4倍增长,阳转率均为100%。抗体GMT分别上升68.45、115.83倍,与对照组抗体GMT差异有非常显著的统计学意义(P<0.001)。结论A群脑膜炎球菌多糖结合疫苗是安全的,有良好的免疫原性。     

A+C群脑膜炎球菌多糖疫苗安全性和免疫原性的研究

目的 以分组对照法观察A＋C群脑膜炎球菌多糖疫苗对6～24月龄幼儿和5～13岁儿童接种后的安全性和免疫原性。方法 观察组共428名儿童,分为2个年龄段接种A＋C群脑膜炎球菌多糖疫苗,接种剂量为每人100μg;阳性对照组103人接种A群脑膜炎球菌多糖疫苗,接种剂量为每人50μg;阴性对照组94人接种伤寒Vi多糖疫苗,接种剂最为每人30μg;各组于接种后6、24、48和72 h测量体温并观察全身和局部反应,并于免疫前、后1个月分别收集血清标本,观察组2个年龄段儿童各不少于50名于免疫后6个月和1年再次收集血清标本,免疫前后收集到的血清采用体外杀菌力试验方法进行杀菌抗体水平的测定。结果 疫苗接种后人体反应轻微,428名儿童仅有3名（0．7%）出现中、强发热反应,有4名（0．9%）出现局部红晕,48h后反应全部消失。5～13岁儿童组免疫后1个月抗A和C群脑膜炎球菌杀菌抗体4倍增长率分别为96．59%和92．15%,免后1年的4倍增长率仍保持在90．91%和90．08%。结论A＋C群脑膜炎球菌多糖疫苗接种后具有较好的安全性和免疫原性。     

A＋C群脑膜炎球菌多糖结合疫苗安全性和免疫原性研究

目的评价A＋C群脑膜炎球菌多糖结合疫苗（Groups A and C Meningococcal Polysaccharide ConjugateVaccine,MCV-A/C）的临床安全性和免疫原性。方法按照随机、盲法、对照、单中心的原则,评价MCV-A/C的临床安全性和免疫原性。结果各年龄组MCV-A/C免疫后,A群、C群血清杀菌力抗体（Serum Bactericidal Antibody,SBA）以及A群和C群SBA同时≥4倍增长率均〉90%。3～5月龄、6～23月龄、2～15岁、16～30岁四个年龄组免疫后,A群、C群SBA几何平均滴度（Geometric Mean Titer,GMT）均〉1：150,达到保护水平以上。各年龄组MCV-A/C和A群脑膜炎球菌多糖疫苗（Meningococcal Polysaccharide Vaccine,MPV）及MPV-A/C免疫后,全身反应及局部反应发生率差异均无统计学意义,未观察到严重的全身和局部反应。结论MCV-A/C在≥3月龄受试者中有良好的安全性和免疫原性。临床试验注册国家食品药品监督管理局《药物临床试验》2006L04776号。     

脑膜炎球菌多糖疫苗安全性及免疫原性评价

目的评价A、C、W₁₃₅和Y群脑膜炎球菌多糖疫苗在2~30岁健康人群中接种的安全性与免疫原性。方法采用随机、双盲和平行对照的设计方法,对A、C、W₁₃₅和Y群脑膜炎球菌多糖疫苗接种人群不良反应发生率、抗体阳转率、平均几何滴度(GMT)进行比较。结果免疫后对照组与试验组总体不良反应发生率分别为11.21%和13.79%,其中全身反应发生率分别为6.06%和5.30%,局部反应发生率分别为6.06%和9.85%;免疫后28d,试验组A、C、W₁₃₅和Y群抗体阳转率均>94.00%,A和C群抗体阳转率与对照组比较差异均无统计学意义(均P>0.05),W₁₃₅和Y群抗体阳转率与对照组比较差异有统计学意义,试验组高于对照组;免疫后抗体GMT分别为A群=394.81、C群=237.32、W₁₃₅群=326.00、Y群=226.45,均达到保护性水平。结论A、C、W₁₃₅和Y群脑膜炎球菌多糖疫苗在2~30岁健康人群中接种有较好的安全性和免疫原性。     

A+C群脑膜炎球菌多糖疫苗安全性观察

目的客观、系统地评价A C群脑膜炎球菌多糖疫苗(MPV)使用后的安全性。方法9 992名2～60岁成人和儿童接种疫苗后,通过抽样主动监测和观察对象主动报告,对速发接种反应、全身反应和局部反应进行观察和统计,并对所有接种者跟踪观察1个月以评价长期的不良反应。结果无速发接种反应发生。在主动监测的人群中,14人有中、强发热反应,发生率1.18%;6人有局部强反应,中、强反应发生率0.51%。在主动报告的人群中,8人有中、强发热反应,发生率0.09%。未观察到与疫苗接种相关的任何长期不良反应。结论此次对A C群MPV使用安全性现场观察,总体接种反应轻微,且发热、红晕等反应均在72h内自行消失,A C群MPV使用后有良好的安全性。     

B群脑膜炎球菌疫苗研究进展

脑膜炎奈瑟菌（Neisseria Meningitidis,Nm）感染仍然严重威胁人群健康,接种疫苗是预防该类疾病的有效手段。根据荚膜多糖的特征,Nm分为A、B、C、W135、Y等不同的血清群。A、C、W135、Y群Nm多糖疫苗以及多糖-蛋白结合疫苗,已经得到广泛应用并证明了其有效性。由于B群Nm菌株的荚膜多糖免疫原性较低,并且与人体神经组织具有同源性,因此B群Nm多糖不能用于疫苗抗原成分。近年来,国际上开展了大量B群Nm蛋白疫苗研究工作,以疫苗外膜蛋白为基础的疫苗研究,以及反向疫苗学技术在B群疫苗研究中的应用,使B群Nm疫苗的研究取得了长足进展。某些B群疫苗显示出良好的免疫原性和有效性,并且已经有B群蛋白疫苗获得许可并规模化应用。     

B群脑膜炎球菌疫苗免疫原性评价技术研究进展

流行性脑脊髓膜炎(流脑)是一种病死率高且后遗症严重的急性呼吸道传染病, 脑膜炎球菌疫苗是预防控制流脑的有效措施。目前, 包括中国在内, B群流脑已成为全球主要流行的血清群。脑膜炎球菌ACYW等疫苗主要成分为荚膜多糖, 而B群脑膜炎球菌疫苗主要成分为蛋白, 有外膜囊泡(OMV)疫苗和重组蛋白疫苗两种。B群脑膜炎球菌疫苗免疫原性的评价方法包括人补体血清杀菌试验(hSBA)及脑膜炎球菌抗原分型系统(MATS)、脑膜炎球菌表面抗原表达试验(MEASURE)、脑膜炎球菌抗原分型系统(gMATS)和Bexsero 疫苗抗原序列分型(BAST)等替代方法。疫苗免疫原性评价技术是疫苗研发和临床试验研究的基础, 而我国目前尚无B群脑膜炎球菌疫苗。因此, 本文就B群脑膜炎球菌疫苗免疫原性评价技术研究进展进行综述, 以期为我国B群脑膜炎球菌疫苗研发和后期免疫原性评价及临床试验研究提供技术指导。     

人群接种A+C群脑膜炎球菌多糖疫苗后安全性和免疫原性研究

目的以分组对照法观察A+C群脑膜炎球菌多糖疫苗对6~24月龄幼儿和5~13岁儿童接种后的安全性和免疫原性。方法观察组共428名儿童,分为2个年龄段接种A+C群脑膜炎球菌多糖疫苗,接种剂量为每人100μg;阳性对照组103人接种A群脑膜炎球菌多糖疫苗,接种剂量为每人50μg;阴性对照组94人接种伤寒V i多糖疫苗,接种剂量为每人30μg。各组于接种后6、24、48和72h测量体温并观察全身和局部反应,并于免疫前、后1个月分别收集血清标本,观察组2个年龄段儿童各不少于50名于免疫后6个月和1年再次收集血清标本,免疫前后收集到的血清采用体外杀菌力试验方法进行杀菌抗体水平的测定。结果疫苗接种后人体反应轻微,428名儿童仅有3名(0.7%)出现中、强发热反应,有4名(0.9%)出现局部红晕,48h后反应全部消失。5~13岁儿童组免疫后1个月抗A和C群脑膜炎球菌杀菌抗体4倍增长率分别为96.59%、92.15%,免疫后1年的4倍增长率仍保持在90.91%和90.08%。结论A+C群脑膜炎球菌多糖疫苗接种后具有较好的安全性和免疫原性。     

A群脑膜炎球菌多糖结合疫苗在6月龄～5岁儿童中的安全性与免疫原性研究

目的 评价A群脑膜炎球菌多糖结合疫苗(Meningococcal Polysaccharide Conjugate Vaccine,MCV)在6月龄～5岁儿童中的安全性和免疫原性.方法 对1339名6月龄～5岁儿童接种1～2剂A群MCV或A群脑膜炎球菌多糖疫苗(Meningococcal Polysaccharide Vaccine,MPV),观察72h内局部和全身反应,测定免疫前后血清杀菌抗体滴度.结果 接种A群MCV或MPV后,均未观察到即时反应,局部和全身反应轻微,发热反应以弱反应为主.6～11月龄接种2剂、1～5岁接种1剂A群MCV后,杀菌抗体几何平均滴度分别为1:891.3和1:924.6,抗体≥4倍增长率分别为98.81%和98.45%.结论 A群MCV对6月龄～5岁儿童具有良好的安全性和免疫原性.临床试验注册 国家食品药品监督管理局药物临床研究批件号:2003L02729、2004L00764.     

A群脑膜炎球菌多糖结合疫苗临床试验--安全性观察报告

目的 :了解 A群脑膜炎球菌多糖结合疫苗的安全性。方法 :于 2 0 0 2年 10月～ 2 0 0 3年 1月 ,在江苏省射阳县对 3～ 4月龄的健康婴幼儿接种 3针 A群脑膜炎球菌多糖结合疫苗 ,以多糖疫苗为对照组 ,进行安全性观察 , 期临床观察4 7人、 ～ 期临床观察 2 36人。结果 :接种 A脑膜炎球菌多糖结合疫苗各针次的副反应均以弱发热反应为主 ,发生率最高为 7.33%、最低为 0 .80 % ,对照组的弱发热反应发生率最高为 1.72 % ,最低为 0 .86 %。结论 :A群脑膜炎球菌多糖结合疫苗具有良好的安全性     

Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou,China

To assess the durability of antibody persistence after substitution of the MPCV vaccine for the MPSV-A vaccine in children, an observational study was conducted in children who voluntarily received two doses of MPCV-AC instead of MPSV-A between March 2017 and March 2018 in Guangzhou, China. In total, 131 and 47 participants were enrolled in the 3-year-old and 6-year-old groups, respectively. In the 3-year-old group, the seroprotection rate and GMT values for Men A and Men C were raised significantly after 1-month post- dose 1 MPSV booster vaccination. All immune indicators were significantly lower in pre- dose 1 MPSV booster vaccination in the 3-year-old group than after pre- dose 2 MPSV booster vaccination in the 6-year-old group. While no significant differences were found in most immune indicators between the 1-month post- dose 1 MPSV booster vaccination in the 3-year-old group and pre- dose 2 MPSV booster vaccination in 6-year-old group. The substitute meningococcal immunization schedule showed a good immunogenicity in young children, and good sequential immunogenicity with MPSV booster immunization.     

Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines

A randomised, open-label study compared the immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) and meningococcal C conjugate vaccine (MnCC vaccine) administered concomitantly and individually. Infants received PCV7 + MnCC vaccine (n = 265), PCV7 alone (n = 268) or MnCC vaccine alone (n = 178). PCV7 was administered at 2, 3½, 6 and 12 months, and MnCC vaccine at 2, 6 and 12 months. For the 7 pneumococcal serotypes tested (4, 6B, 9V, 14, 18C, 19F and 23F), proportions of subjects with pneumococcal serotype-specific immunoglobulin G (IgG) antibody concentrations ≥0.35 μg/mL post-infant series were non-inferior for the PCV7 + MnCC vaccine (91.5–99.6%) and PCV7 (89.0–99.6%) groups. Proportions of subjects achieving serogroup C meningococcal serum bactericidal assay titres ≥1:8 post-infant series were non-inferior for the PCV7 + MnCC vaccine (99.6%) and MnCC vaccine groups (98.8%). Pneumococcal IgG antibody levels were similar in the PCV7 + MnCC vaccine and PCV7 groups at each time point. Post-infant and post-toddler meningococcus C serum bactericidal assay titres and IgG levels were similar in the PCV7 + MnCC vaccine and MnCC groups, although pre-toddler, the levels were lower in the PCV7 + MnCC vaccine group than the MnCC vaccine group. Immune response rates to diphtheria antigen approached 100% for all vaccine groups. Local reactions were mostly similar among the treatment groups. The MnCC vaccine group had lower rates of some systemic events than the PCV7 + MnCC vaccine group. Immune responses to PCV7 + MnCC vaccine were non-inferior compared with those seen with each vaccine administered alone.     

Efficacy,immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized,double-blind,placebo-controlled trial

BackgroundA randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy, immunogenicity and safety of a novel trivalent live human-lamb reassortant rotavirus vaccine (LLR3) against rotavirus gastroenteritis (RVGE).MethodsHealthy children aged 6–13 weeks were enrolled and randomized (1:1) to either 3 oral doses of LLR3 or placebo according to a 0, 1, 2 month schedule. The objectives were to evaluate vaccine efficacy (VE) against RVGE of any-severity, severe RVGE (sRVGE) and inpatient caused by rotavirus serotypes contained in the vaccine and not contained in the vaccine after the third dose. Immunogenicity was also assayed in a subgroup. All adverse events (AEs) were collected from 30 min after each dose for immediate reaction, even to the entire study period, including the serious AEs (SAEs) and intussusception.ResultsVE against RVGE of any-severity, sRVGE and inpatient caused by any serotype was 56.6% (95% CI: 50.7, 61.8), 70.3% (95% CI: 60.6, 77.6) and 74.0% (95% CI: 57.5, 84.1) respectively. VE against RVGE of any-severity, sRVGE caused by serotypes not contained in vaccine were 54.2% (95% CI: 47.5, 60.1) and 70.4% (95% CI: 60.4, 77.9). The rate of seroconversion and four-fold increase of rotavirus serotype G2-, G3-, and G4-specific IgA is 60.8%, 58.0%, and 60.6% in vaccine group, which was higher than 21.35%, 22.7%, and 23.1% in placebo group (p < 0.0001 for G2, G3, G4), as well as the Geometric Mean Titer (GMT). Through the entire trial, 65.91% and 67.79% of participants reported at least one AE, and 0.02% and 0.02% reported SAEs in the vaccine and placebo groups, respectively. Two intussusception cases were reported both in vaccine and placebo group.ConclusionsIn Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.     

A phase II,single-center,randomized, double-blind,parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine

BackgroundThis was a single-center, randomized, double-blind, parallel control study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine with tetanus toxoid (TT) conjugate protein, in infants and toddlers of 3–35 months old.Method720 participants were stratified according to the age of 3–5 months old, 6–11 months old, and 12–35 months old and randomly assigned with an equal ratio to two different dose groups, i.e., 40- and 20-μg doses. Blood samples were taken from all participants before the first vaccination and 30 days after the full-course vaccination to detect the serogroups ACYW meningococcal antibodies. All adverse events occurred within 30 days after vaccination of each dose, and serious adverse events occurred within six months after full-course vaccination were collected for safety evaluation. This study was registered at the China drug trial registration with the identifier CTR 20182031.ResultsAfter 30 days of full-course vaccination, 92.78 % (95 % CI: 85.70 %-100.00 %) showed the immune response against all serogroups in both high-dose and low-dose groups by rabbit serum bactericidal antibody assay (rSBA) and the geometric mean titer (GMT) of all serogroups showed a high level (74.6–505.8, 95 % CI: 56.4–615.7). However, no significant difference between different dose groups was observed (P > 0.05). The common local and systemic adverse events in both groups were redness (3 %-7%), and fever (26 %-65 %), respectively. In addition, the grade 3 adverse event related to the vaccine was fever (1.67 %-12.50 %). No serious adverse event was reported to be associate with the vaccination.ConclusionThe serogroups ACYW meningococcal polysaccharide conjugate vaccine was safe and effective in the population aged 3–35 months. The vaccine efficacy and safety of the 20-μg dose group were not less than that of the 40-μg dose group.     

Efficacy,immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

Background

A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra?, Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged?≥?3?years. This study examined the efficacy and safety of IIV4 in children aged 6–35?months.

Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults

The immune responses induced in young adults by a meningococcal A/C polysaccharide-diphtheria toxoid conjugate vaccine (Mcj) and a meningococcal A/C plain polysaccharide vaccine (Mps) were evaluated in unvaccinated subjects and those who had received either vaccine previously. 195 subjects aged 17-30 years received either Mps or Mcj. After 12 months, they were randomised again to receive a second dose of either vaccine. Serogroup specific serum bactericidal assay (SBA) titers and IgG antibody responses were assayed before and 4-8 weeks after primary and booster immunisation. Both vaccines were immunogenic in previously unvaccinated subjects. Administration of a dose of Mps after previous Mps or Mcj induced lower bactericidal titers to group C Neisseria meningitidis than those seen after a single dose of Mps. Bactericidal antibody responses to Mcj were not reduced in subjects who had previously received Mps.     

Evaluation of safety and immunogenicity of feline vaccines with reduced volume

A non adjuvanted vaccine against feline herpesvirus, feline calicivirus, feline panleucopenia and feline leukemia has been formulated in reduced volume (0.5 ml) with the same antigen content as the conventional 1 ml presentation. This paper reports studies evaluating the safety and the immunogenicity of this reduced volume vaccine in comparison with the conventional volume vaccine. The safety of both vaccines was evaluated in a small sized laboratory trial. It was further tested in a randomized controlled field trial on a total of 398 cats. Immediate and delayed local and systemic adverse events were monitored after vaccination. The immunogenicity of each vaccine was also checked by serological antibody responses against the vaccines antigens during the laboratory trial.These studies showed that the 0.5 ml vaccine was well tolerated in cats, inducing less local events, while keeping the same immunogenicity as the corresponding 1 ml vaccine. Reducing the volume of the vaccine is a way to improve the convenience of administration and to help following vaccination guidelines with the aim of reducing the incidence of adverse events following vaccination.     

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age

Background

Routine administration of quadrivalent meningococcal conjugate vaccine to adolescents and certain high risk groups is recommended in the United States and Canada. We compared the immunogenicity and safety of an investigational quadrivalent meningococcal vaccine conjugated to CRM-197 (MenACWY-CRM) with a licensed quadrivalent vaccine conjugated to diphtheria toxoid (MCV4) in children aged 2–10 years.

Methods

Eligible 2–5-year-olds were randomized 1:2:2 to receive either 2 doses of MenACWY-CRM, or 1 dose of MenACWY-CRM or MCV4; 6–10-year-olds were randomized 1:1 to receive a single dose of MenACWY-CRM or MCV4. The primary immunogenicity assessment was seroresponse separately for the two age cohorts 28 days following a single dose of MenACWY-CRM or MCV4. Noninferiority and superiority criteria were predefined. Solicited injection-site and systemic reactions were collected for the 7 days postvaccination.

Results

A total of 2907 children were randomized to receive study vaccine. MenACWY-CRM met statistical superiority criteria vs. MCV4 for groups W and Y and was noninferior for group C in both age strata. For group A, noninferiority criteria were not met; the group A seroresponse rates for MenACWY-CRM and MCV4, respectively were 72% (95% confidence interval 68–75%) and 77% (73–80%) in 2–5-year-olds and 77% (73–80%) and 83% (79–86%) in 6–10-year-olds. When the two age strata were combined (2–10-year-old children), MenACWY-CRM was noninferior to MCV4 for all four groups, and statistically superior for groups C, W, and Y. Safety parameters were similar across age cohorts and vaccines groups.

Conclusions

MenACWY-CRM and MCV4 were immunogenic and well tolerated in children aged 2–10 years. Seroresponse to MenACWY-CRM was statistically noninferior to MCV4 for all groups, and statistically superior for groups C, W, and Y.

Trial registration

Clinicaltrials.gov identifier: NCT00616421.     

Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents

BackgroundChildren and adolescents are susceptible to influenza. Vaccination is the most important strategy for preventing influenza, yet there are few studies on the immunogenicity and safety of quadrivalent inactivated influenza vaccine (QIV) containing two A strains (H1N1 and H3N2) and two B lineages (Victoria and Yamagata). Therefore, to further clarify the immunogenicity and safety of QIV in children and adolescents, a meta-analysis was performed to provide a reference for the development of influenza prevention strategies.MethodsPubMed, EMBASE and Cochrane Library were searched for articles published as of February 12, 2019. Random clinical trials comparing the immunogenicity and safety of QIV and TIV among children and adolescents were selected. The main outcomes were comparisons of immunogenicity (seroprotection rate [SPR] and seroconversion rate [SCR] and adverse events using risk ratios (RRs). The meta-analysis was performed using random-effects models.ResultsAmong the 6 months up to 3 years group, QIV showed a higher SPR for B lineages than for TIV-B/Yamagata, with pooled RRs of 3.07 (95% CI: 2.58–3.66) and 1.06 (95% CI: 1.01–1.11), respectively. For the 3 years through 18 years, QIV had a higher SCR and SPR for the Yamagata lineage than for TIV-B/Victoria, with pooled RRs of 2.30 (95% CI: 1.83–2.88) and 1.16 (95% CI: 1.03–1.30), respectively. Compared to TIV-B/Yamagata, a higher SCR and SPR for the Victoria lineage was found for QIV, with RRs of 3.09 (95% CI: 1.99–4.78) and 1.72 (95% CI: 1.22–2.41), respectively. Regarding adverse events, only pain was more frequently reported for QIV than TIV ; the RR was 1.09 (95% CI: 1.02–1.17).ConclusionsThe immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TIV.     

贵州省脑膜炎球菌多糖疫苗不同免疫策略的成本-效果比较分析

目的 比较分析贵州省脑膜炎球菌多糖疫苗（meningococcal polysaccharide vaccine,MPV）推广使用和纳入免疫规划策略的成本-效果。方法 根据贵州省MPV接种、流脑发病情况,采用成本-效果分析法,计算贵州省不同阶段推广使用MPV和将MPV纳入免疫规划策略的成本-效果比值（cost-effectiveness ratio,CER）。结果 1999—2015年,贵州省共接种6 285.73万剂次MPV,共减少流脑发病94 069例,减少致残13 170例,减少死亡10 710例;推广使用MPV、将MPV纳入免疫规划免疫策略总投入成本8.20亿元,26年间,接种MPV每减少1例流脑病例投入的成本为6 952元,其中,1990—2005年推广使用MPV 、2006—2015年纳入免疫规划策略每减少1例流脑病例投入的成本分别为4 915.64、614.59元。结论 接种MPV对降低贵州省流脑发病水平具有良好的成本-效果,2006—2015年将MPV纳入免疫规划策略的成本-效果明显优于1990—2005年推广使用MPV策略。